Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Neuroendocrine Carcinoma (NEC)”

43 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 43 results

Testing effectiveness (Phase 2)Looking for participantsNCT06157827
What this trial is testing

A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma

Who this might be right for
Advanced Neuroendocrine Carcinoma
Nanjing Leads Biolabs Co.,Ltd 178
Large-scale testing (Phase 3)Looking for participantsNCT05058651
What this trial is testing

Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

Who this might be right for
Advanced Extrapulmonary Neuroendocrine CarcinomaMetastatic Extrapulmonary Neuroendocrine CarcinomaRecurrent Extrapulmonary Neuroendocrine Carcinoma+1 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Looking for participantsNCT06393816
What this trial is testing

FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum

Who this might be right for
Large Cell Neuroendocrine Carcinoma of the Lung
Centre Leon Berard 80
Post-approval studies (Phase 4)Study completedNCT01317615
What this trial is testing

RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation

Who this might be right for
Carcinoma, Large CellNeuroendocrine Tumors
Novartis Pharmaceuticals 49
Testing effectiveness (Phase 2)Study completedNCT02955069
What this trial is testing

Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)

Who this might be right for
Well-differentiated Non-functional NET of Thoracic OriginWell-differentiated Non-functional NET of Gastrointestinal OriginWell-differentiated Non-functional NET of Pancreatic Origin+1 more
Novartis Pharmaceuticals
Testing effectiveness (Phase 2)Study completedNCT03147404
What this trial is testing

Phase II Study of Avelumab in Metastatic Gastronetro-pancreatic （GEP） Neuroendocrine Carcinoma （NEC, WHO Grade 3） as Second-line Treatment After Failing to Etoposide+Cisplatin: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes

Who this might be right for
Neuroendocrine Carcinoma, Grade 3
Samsung Medical Center 14
Not applicableUnknownNCT06400654
What this trial is testing

PrognostIc and Predictive Factors in Unresectable Locally Advanced NEC and MANEC

Who this might be right for
Neuroendocrine Carcinoma
European Institute of Oncology 100
Testing effectiveness (Phase 2)UnknownNCT05142865
What this trial is testing

Camrelizumab Combined With Chemotherapy and Apatinib for Extrapulmonary Neuroendocrine Carcinomas

Who this might be right for
Advanced or Metastatic EP-NEC
Huazhong University of Science and Technology 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07510594
What this trial is testing

A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NEC

Who this might be right for
Large-Cell Neuroendocrine Carcinoma of the LungExtrapulmonary Neuroendocrine Carcinoma
Tianjin Medical University Cancer Institute and Hospital 48
Early research (Phase 1)Not Yet RecruitingNCT07488923
What this trial is testing

A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)

Who this might be right for
Small Cell Lung Cancer (SCLC )Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)Gastroenteropancreatic NEC (GEP NEC)+1 more
Moonlight Bio, Inc 110
Testing effectiveness (Phase 2)Looking for participantsNCT06406465
What this trial is testing

A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

Who this might be right for
Carcinoma, NeuroendocrineTumor, NeuroendocrineTumors, Neuroendocrine+2 more
National Cancer Institute (NCI) 60
Testing effectiveness (Phase 2)Looking for participantsNCT07129252
What this trial is testing

Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors

Who this might be right for
SST2-positive Neuroendocrine NeoplasmsNeuroendocrine TumorsNeuroendocrine Neoplasm
Crinetics Pharmaceuticals Inc. 150
Not applicableUnknownNCT04720391
What this trial is testing

Bone Metastases in neurOendocrine NEoplasms: naTural History, Prognostic Impact and Therapeutic Approach (MONET)

Who this might be right for
Bone MetastasesNeuroendocrine Neoplasm
European Institute of Oncology 500
Testing effectiveness (Phase 2)Looking for participantsNCT07038096
What this trial is testing

ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma

Who this might be right for
Small Cell Lung CancerNeuroendocrine Carcinoma
Suzhou Zelgen Biopharmaceuticals Co.,Ltd 350
Testing effectiveness (Phase 2)Looking for participantsNCT07518602
What this trial is testing

Efficacy and Safety of Chidamide+Sintilimab+Bev as Second-Line Therapy in Advanced Extrapulmonary Neuroendocrine Carcinoma

Who this might be right for
Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)
Sun Yat-sen University 34
Testing effectiveness (Phase 2)Active Not RecruitingNCT04701307
What this trial is testing

Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas

Who this might be right for
Lung Small Cell CarcinomaNeuroendocrine CarcinomaStage III Lung Cancer AJCC v8+3 more
M.D. Anderson Cancer Center 48
Testing effectiveness (Phase 2)Study completedNCT03352934
What this trial is testing

Avelumab Treatment in Patients With Neuroendocrine Carcinomas (NEC G3) Progressive After Chemotherapy

Who this might be right for
Cancer
Johannes Gutenberg University Mainz 60
Early research (Phase 1)Looking for participantsNCT07006727
What this trial is testing

Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors

Who this might be right for
Small Cell Lung CarcinomaLarge Cell Neuroendocrine Carcinoma of the LungNeuroendocrine Prostate Cancer+1 more
Novartis Pharmaceuticals 116
Testing effectiveness (Phase 2)Study completedNCT01480986
What this trial is testing

IPO-NEC Trial:Study on the Efficacy and Safety Using Sequential IP Therapy and Oct Lar in the Treatment of Advanced GI NEC

Who this might be right for
Progression Free Survival of the Treatment
Peking University 40
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07337447
What this trial is testing

Trial of FOLFIRI + Zimberelimab + Domvanalimab vs FOLFIRI With a Hybrid Synthetic Control Arm in Second Line Treatment of Neuroendocrine Carcinoma of Gastro-enteropancreatic or Unknown Origin (REWENEC 01)

Who this might be right for
Carcinoma, Neuroendocrine
Hospices Civils de Lyon 122
Load More Results
189
116